Filters
Modern approach to the field of primary immunodeficiencies translating precise molecular and functional diagnosis to therapy (NV18-05-00162)
Primary immunedeficiencies (PIDs) are rare diseases of the immune system, manifesting primarily as increased susceptibility to infections, their more severe course, but also immune dysregulations, such as lymphoproliferation or autoimmunity. The diag...
Immunology
- 2018 - 2021 •
- 9 919 tis. Kč •
- 9 919 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2018 - 31. 12. 2021
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Genomic study of a climate-driven population replacement (LH15255)
The principal aim is to test the hypothesis that a climate-driven population replacement similar to that in Britain occurred also in other parts of Europe, specifically during the colonization of Scandinavia. Using cutting-edge methods of population ...
EG - Zoologie
- 2016 - 2017 •
- 1 942 tis. Kč •
- 1 942 tis. Kč •
- MŠMT
Řešení projektu: 4. 1. 2016 - 31. 12. 2017
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo školství, mládeže a tělovýchovy
Activity of novel compounds against Burkholderia cenocepacia a study of genome and transcriptome in respect to bacterial evolution in the human host (NV15-28017A)
The most problematic respiratory pathogens in patients with cystic fibrosis (CF) are arguably bacteria from Burkholderia cepacia complex (Bcc) as they cause fatal infections, untreatable by current antibiotics. Recently, first promising compounds wit...
EE - Mikrobiologie, virologie
- 2015 - 2018 •
- 4 602 tis. Kč •
- 4 602 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2015 - 31. 12. 2018
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Using MALDI-TOF mass spectrometry for identification of molecular patterns in relapsed multiple myeloma patients (NU21-03-00076)
Multiple myeloma is the second most common hematological malignancy of the elderly. Median age at diagnosis is 65. Bone marrow transplants as well as new drugs (immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies) significantly in...
Hematology
- 2021 - 2024 •
- 10 729 tis. Kč •
- 10 729 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2021 - 31. 12. 2024
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
ESTABLISHING GENETIC DIAGNOSIS IN CHILDREN WITH GROWTH DISORDERS USING NEXT GENERATION SEQUENCING METHODS - A PATHWAY TOWARDS INDIVIDUALIZED THERAPY (NV16-31211A)
Human growth is strongly genetically determined. Four clinically defined conditions with short stature of unknown origin include (1) familiar short stature, (2) idiopathic short stature, (3) intrauterine growth retardation followed by postnatal growt...
FG - Pediatrie
- 2016 - 2019 •
- 10 673 tis. Kč •
- 10 673 tis. Kč •
- MZ
Řešení projektu: 1. 4. 2016 - 31. 12. 2019
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Genetics of adult-onset familial focal segmental glomerulosclerosis (FSGS) – implications for individualized therapy and successful kidney transplantation (NV19-06-00443)
Focal segmental glomerulosclerosis (FSGS) is a clinically and genetically heterogeneous entity that manifests mostly by proteinuria. FSGS is responsible for about 15% of end-stage renal disease (ESRD) cases requiring hemodialysis or renal transplanta...
Human genetics
- 2019 - 2023 •
- 13 856 tis. Kč •
- 12 179 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2019 - 31. 12. 2023
Uznané náklady
Podpora ze státního rozpočtu (88%)
Poskytovatel: Ministerstvo zdravotnictví
High-throughput genomic profiling for personalised diagnostics and treatment of haematopoietic disorders in children (NV15-30626A)
Contemporary high-throughput genomic techniques including Next Generation Sequencing and Single Nucleotide Polymorphism analysis allow individual characterization of childhood patients suffering from selected haematopoietic disorders. Current project...
FG - Pediatrie
- 2015 - 2019 •
- 19 097 tis. Kč •
- 19 097 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2015 - 31. 12. 2019
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Next generation sequencing for early diagnosis and individualized therapy of hypertrophic cardiomyopathy (NV15-34904A)
Cardiomyopathies (CMP) are a heterogeneous group of diseases with impaired cardiac structure and/or function, which represent an important cause of cardiovascular morbidity and mortality, and are often hereditary. Hypertrophic cardiomyopathy is the m...
FA - Kardiovaskulární nemoci včetně kardiochirurgie
- 2015 - 2018 •
- 11 717 tis. Kč •
- 11 717 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2015 - 31. 12. 2018
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Feasibility study of next generation sequencing for individualized therapy of patients with solid tumors (NV19-08-00113)
Search for molecular biomarkers enabling prediction of cancer treatment efficacy and establishment of optimal method for their assessment represent major opportunities, but also challenges in translational research. This project aims to explore feasi...
Medical laboratory technology (including laboratory samples analysis; diagnostic technologies) (Biomaterials to be 2.9 [physical characteristics of living material as related to medical implants, devices, sensors])
- 2019 - 2023 •
- 8 710 tis. Kč •
- 8 670 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2019 - 31. 12. 2023
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Importance of ovarian carcinoma genetic profile in prevention of development, progression and suboptimal treatment response (NU20-09-00174)
Ovarian carcinoma (OC) is a leading cause of death among gynecological cancers. In order to improve prevention, screening and reduction of high mortality, it is necessary to reveal genetic variability of OC and its association with environmental risk...
Human genetics
- 2020 - 2024 •
- 15 028 tis. Kč •
- 12 521 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2020 - 31. 12. 2024
Uznané náklady
Podpora ze státního rozpočtu (83%)
Poskytovatel: Ministerstvo zdravotnictví
- 1 - 10 out of 155